Biochip Detecting GPNMB Gene Expression for Lung Adenocarcinoma Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tracking postoperative recurrence status of lung adenocarcinoma patients are time-consuming, costly, and increase the risk of infectious disease transmission due to the need for frequent hospital visits and lengthy diagnostic processes, particularly when dealing with drug resistance after target drug therapy.
Innovation Solution
A biochip that measures the expression amount of the GPNMB gene using a sensing electrode with a biological agent, such as an antibody, capable of detecting mRNA or protein levels, allowing for real-time and cost-effective tracking of recurrence status with a sample as small as one drop of blood.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional X-ray imaging or NGS/ELISA methods are used for diagnosis, then detection accuracy is maintained, but detection time increases and cost increases
Solution Approach 1:
The patent segments the complex NGS/ELISA diagnostic process into a simplified electrochemical detection system using a biochip with sensing electrode and specific antibodies, enabling direct measurement without lengthy sample preparation and analysis procedures
Solution Approach 2:
The patent replaces the mechanical/chemical complex processes of NGS and ELISA with an electrochemical detection system that measures electrical signals directly, significantly reducing detection time while maintaining accuracy
2Measurement precision
If traditional NGS or ELISA methods are used, then biomarker detection is achieved, but cost increases
Solution Approach 1:
The patent employs a disposable biochip design with inexpensive electrochemical components and small amounts of antibodies, replacing expensive reusable equipment and reagents required for NGS and ELISA, thereby significantly reducing per-test cost
Solution Approach 2:
The patent extracts only the essential detection function from complex laboratory systems, using a simplified electrochemical sensor that requires minimal sample preparation and no expensive equipment, making high-precision biomarker detection affordable
3Measurement precision
If frequent hospital visits are required for tracking, then monitoring accuracy is improved, but infectious disease transmission risk increases
Solution Approach 1:
The patent enables patients to perform self-testing at home using the portable biochip, eliminating the need for frequent hospital visits while maintaining monitoring accuracy, thereby reducing infectious disease transmission risk in healthcare settings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biochip provides rapid, affordable, and accurate detection of lung adenocarcinoma recurrence, reducing medical costs and minimizing hospital overcrowding by enabling early treatment through real-time monitoring of GPNMB gene expression levels, particularly effective in cases of drug resistance to target drugs like Iressa.
Implementation Method 1
the sensing electrode comprises a biological agent capable of measuring an expression amount of the GPNMB gene
Data Source
AI summary
The present invention provides a biochip for tracking postoperative recurrence status of a patient with lung adenocarcinoma. The biochip comprises a bare plate layer, the bare plate layer comprises a sensing electrode, and the sensing electrode comprises a biological agent capable of measuring an expression amount of a GPNMB gene. The present invention further provides a method for tracking the postoperative recurrence status of a patient with lung adenocarcinoma. The method comprises the following steps: step one, providing a sample from a patient with lung adenocarcinoma; step two: contacting the sample with a carrier capable of detecting an expression amount of a GPNMB gene; and step three: analyzing a change of the expression amount of the GPNMB gene to track the postoperative recurrence status of the patient with lung adenocarcinoma. The present invention utilizes a mass production capability of a semiconductor lithography process to control a chip cost, achieves an effect of a quick examination by using one drop of blood, can track the postoperative recurrence status of a patient with lung adenocarcinoma in real time so as to perform early treatment, and reduces a medical cost of the patient with lung adenocarcinoma.